Abstract:Background and aims: Although type 2 innate lymphoid cells (ILC2s) were originally found to be liver-resident lymphocytes, the role and importance of ILC2 in liver injury remains poorly understood. In the current study, we sought to determine whether ILC2 is an important regulator of hepatic ischaemia/reperfusion injury (IRI). Methods: ILC2-deficient mice (ICOS-T or NSG) and genetically modified ILC2s were used to investigate the role of ILC2s in murine hepatic IRI. Interactions between ILC2s and eosinophils or macrophages were studied in coculture. The role of human ILC2s was assessed in an immunocompromised mouse model of hepatic IRI. Results: Administration of IL-33 prevented hepatic IRI in association with reduction of neutrophil infiltration and inflammatory mediators in the liver. IL-33-treated mice had elevated numbers of ILC2s, eosinophils, and regulatory T cells. Eosinophils, but not regulatory T cells, were required for IL-33-mediated hepatoprotection in IRI mice. Depletion of ILC2s substantially abolished the protective effect of IL-33 in hepatic IRI, indicating that ILC2s play critical roles in IL-33-mediated liver protection. Adoptive transfer of ex vivo-expanded ILC2s improved liver function and attenuated histologic damage in mice subjected to IRI. Mechanistic studies combining genetic and adoptive transfer approaches identified a protective role of ILC2s through promoting IL-13-dependent induction of anti-inflammatory macrophages and IL-5-dependent elevation of eosinophils in IRI. Furthermore, in vivo expansion of human ILC2s by IL-33 or transfer of ex vivo-expanded human ILC2s ameliorated hepatic IRI in an immunocompromised mouse model of hepatic IRI. Conclusions: This study provides insight into the mechanisms of ILC2-mediated liver protection that could serve as therapeutic targets to treat acute liver injury. Impact and implications: We report that type 2 innate lymphoid cells (ILC2s) are important regulators in a mouse model of liver ischaemia/reperfusion injury (IRI). Through manipulation of macrophage and eosinophil phenotypes, ILC2s mitigate liver inflammation and injury during liver IRI. We propose that ILC2s have the potential to serve as a therapeutic tool for protecting against acute liver injury and lay the foundation for translation of ILC2 therapy to human liver disease.

Liver type 1 innate lymphoid cells develop locally via an interferon-γ–dependent loop

Ambiguous roles of innate lymphoid cells in chronic development of liver diseases

Ly49E Separates Liver ILC1s into Embryo-Derived and Postnatal Subsets with Different Functions

Innate-like T cells in liver disease

Group 1 ILCs: Heterogeneity, plasticity, and transcriptional regulation

Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability

Recipient tissue microenvironment determines developmental path of intestinal innate lymphoid progenitors

Innate lymphoid cells — how did we miss them?

Tissue specific imprinting on innate lymphoid cells during homeostasis and disease process revealed by integrative inference of single-cell transcriptomics

Type 3 Innate Lymphoid Cell: a New Player in Liver Fibrosis Progression

The Origin and Role of Innate Lymphoid Cells in the Lung

Transcriptional Regulatory Network for the Development of Innate Lymphoid Cells

Lymphoid Tissue Inducer-a Divergent Member of the ILC Family.

Differential Phenotypic and Functional Properties of Liver-Resident NK Cells and Mucosal ILC1s.

Type 2 innate lymphoid cells are protective against hepatic ischaemia/reperfusion injury

Isolation and characteristics of murine hepatic innate lymphocytes

Intrahepatic Development of Liver-Resident Natural Killer Cells (LYM2P.739)

Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer

Transcriptional control of ILC identity

Identification and characterization of innate lymphoid cells generated from pluripotent stem cells